Canopy Growth Corp Expands Spectrum Therapeutics Portfolio in Australia with Softgel Capsules

Canopy Growth Corp has expanded its Spectrum Therapeutics portfolio in Australia with softgel capsules to target more medical cannabis patients in the country. The addition of three softgel formats aims to capitalize on growing demand as the Australian cannabis market matures. The move follows the company's Q2 earnings, which showed a 12% increase in revenue to C$51 million. Analyst Bill Kirk reiterated a Buy rating with a price target of C$8.00.